Akebia Therapeutics (AKBA)

$2.85 -0.10 (-3.39%)
Market Cap 782.18M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -43.33%
Debt to Equity Ratio 1.61
Volume 2,576,000
Avg Vol 3,712,272
Day's Range N/A - N/A
Shares Out 265.15M
Stochastic %K 53%
Beta 0.68
Analysts Strong Sell
Price Target $7.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
Thomasboy1
Thomasboy1 Oct. 9 at 4:03 PM
$AKBA BIDZIL has that ruler all under control. Take us up Sir!
0 · Reply
Thomasboy1
Thomasboy1 Oct. 9 at 4:00 PM
$AKBA Yup… 👍
0 · Reply
buckeye1979
buckeye1979 Oct. 9 at 4:00 PM
$AKBA always posting negative comments with zero analysis or reasoning behind it. Why accuse Pithy of being paid when you do this all day with zero information to back it up?
1 · Reply
PharmaExpert
PharmaExpert Oct. 9 at 3:56 PM
$AKBA 1m volume! 🔥
1 · Reply
PlsStonks
PlsStonks Oct. 9 at 3:56 PM
$AKBA
0 · Reply
SlapThatAsssk
SlapThatAsssk Oct. 9 at 3:53 PM
$AKBA - this @Bluefin1976 🤡 has to be the biggest moron on this board. Respect everyone’s opinion but he posts nonsense daily - easy block
1 · Reply
Thickhog81
Thickhog81 Oct. 9 at 3:51 PM
$AKBA oh good thing I sold everything yesterday because of grinch and fish and all the other trolls j/k lmao 🤣 know what you own! 😏🤑💰 🐮 🦗
0 · Reply
PharmaExpert
PharmaExpert Oct. 9 at 3:50 PM
$AKBA I am seeing many big green bars today! 🔥
0 · Reply
JacobLandry
JacobLandry Oct. 9 at 3:43 PM
$AKBA very interesting how many fake profiles are popping up, hmm 🤔
0 · Reply
NYS009
NYS009 Oct. 9 at 3:36 PM
$AKBA thats a lot of consolidation
0 · Reply
Latest News on AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 4:05 PM EDT - 7 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:34 AM EDT - 4 weeks ago

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 4:05 PM EDT - 5 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 28, 2025, 8:17 AM EDT - 6 weeks ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 28, 2025, 8:00 AM EDT - 6 weeks ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 21, 2025, 8:00 AM EDT - 7 weeks ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:34 PM EDT - 2 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 2 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Aug 4, 2025, 8:00 AM EDT - 2 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 31, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Jun 4, 2025, 8:00 AM EDT - 4 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 27, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:44 PM EDT - 5 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 5 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Apr 3, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Mar 20, 2025, 8:18 AM EDT - 7 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 10:17 PM EDT - 7 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 7 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 10:21 AM EDT - 7 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 13, 2025, 7:00 AM EDT - 7 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Mar 6, 2025, 8:00 AM EST - 7 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Feb 10, 2025, 5:43 AM EST - 8 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 13, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 10 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Dec 3, 2024, 7:00 AM EST - 11 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 25, 2024, 8:00 AM EST - 11 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 11 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 14, 2024, 8:00 AM EST - 11 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:00 AM EST - 11 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 1:59 PM EST - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 7, 2024, 7:00 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 10, 2024, 8:00 AM EDT - 1 year ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jul 11, 2024, 6:00 AM EDT - 1 year ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 27, 2024, 8:18 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Jun 24, 2024, 8:58 AM EDT - 1 year ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

Thomasboy1
Thomasboy1 Oct. 9 at 4:03 PM
$AKBA BIDZIL has that ruler all under control. Take us up Sir!
0 · Reply
Thomasboy1
Thomasboy1 Oct. 9 at 4:00 PM
$AKBA Yup… 👍
0 · Reply
buckeye1979
buckeye1979 Oct. 9 at 4:00 PM
$AKBA always posting negative comments with zero analysis or reasoning behind it. Why accuse Pithy of being paid when you do this all day with zero information to back it up?
1 · Reply
PharmaExpert
PharmaExpert Oct. 9 at 3:56 PM
$AKBA 1m volume! 🔥
1 · Reply
PlsStonks
PlsStonks Oct. 9 at 3:56 PM
$AKBA
0 · Reply
SlapThatAsssk
SlapThatAsssk Oct. 9 at 3:53 PM
$AKBA - this @Bluefin1976 🤡 has to be the biggest moron on this board. Respect everyone’s opinion but he posts nonsense daily - easy block
1 · Reply
Thickhog81
Thickhog81 Oct. 9 at 3:51 PM
$AKBA oh good thing I sold everything yesterday because of grinch and fish and all the other trolls j/k lmao 🤣 know what you own! 😏🤑💰 🐮 🦗
0 · Reply
PharmaExpert
PharmaExpert Oct. 9 at 3:50 PM
$AKBA I am seeing many big green bars today! 🔥
0 · Reply
JacobLandry
JacobLandry Oct. 9 at 3:43 PM
$AKBA very interesting how many fake profiles are popping up, hmm 🤔
0 · Reply
NYS009
NYS009 Oct. 9 at 3:36 PM
$AKBA thats a lot of consolidation
0 · Reply
DollaDollaPils
DollaDollaPils Oct. 9 at 3:21 PM
$AKBA
1 · Reply
Gcordak1
Gcordak1 Oct. 9 at 3:20 PM
$AKBA y’all think we stay in the 290s today or do we get another rug pool???
1 · Reply
PharmaExpert
PharmaExpert Oct. 9 at 3:10 PM
$AKBA is looking bullish!
0 · Reply
RemitTekram
RemitTekram Oct. 9 at 2:59 PM
$AKBA Shorties... We're here for you.
0 · Reply
Brb5010
Brb5010 Oct. 9 at 2:56 PM
$AKBA
0 · Reply
jacksparo
jacksparo Oct. 9 at 2:56 PM
$AKBA Not bad but overall it needs another strong earning . I am still holding.
1 · Reply
StockHawkZero
StockHawkZero Oct. 9 at 2:38 PM
$AKBA I wonder, can they get it back to 2.8?
1 · Reply
ROCKET123
ROCKET123 Oct. 9 at 2:30 PM
$AKBA XBI rocketing, we still in the crapper…hmmm💎
0 · Reply
Nixblicker
Nixblicker Oct. 9 at 2:06 PM
$AKBA everything is running up to infinity. But only Akba is not
1 · Reply
jd_76
jd_76 Oct. 9 at 1:36 PM
$AKBA so one of my other stocks that I’m in is having their earnings call today and it’s green earnings and guess what the stock went up not down. I’m not used to that 🤣
0 · Reply
Rio307
Rio307 Oct. 9 at 1:15 PM
$AKBA I love myself some good hammock time but the job of working in PR for Akebia is relaxing even by my standards. I don't even remember the last time we get a pr for anything other than inducements. Considering this is "the most exciting time in the history of the company," it seems like they should have something to brag about.
4 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 9 at 1:15 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AKBA Current Share Price: $2.85 Contracts: $AKBA January 15, 2027 $4 Calls Scale in: $0.68- $0.83 Scale out: $1.05-$1.35 Can Easily Capture: 60% ROI Blended DTE: 463 Days | Join Elites here: https://liquidtheta.com/
0 · Reply